Fundam Clin Pharmacol

This study assessed in depth the use of first‐ and second‐generation antipsychotic (FGAP/SGAP) drugs in France. A 1/97th random sample of beneficiaries affiliated to the French Health Insurance system—Echantillon Généraliste des Bénéficiaires (EGB)—was used: (i) 621 662 persons in 2015 among which 11 319 had an antipsychotic (AP) prescription; (ii) a sample of first AP prescriptions concerning 5 935 patients in 2013 and 2014 (no AP in the last 6 months of 2012) for whom diagnosis was available in 40% of cases. In 2015, AP prevalence was 21.9/1 000. SGAP/FGAP ratio was 1.02. Long‐lasting prescriptions were rare: 1.79/1 000 for FGAP and 1.38/1 000 for SGAP. FGAP first prescriptions were higher than SGAP for each age class, except for <18 aged patients; 2.85% had both generations; 50.7% of the patients had another psychotropic. GPs prescribed more FGAPs than SGAPs, psychiatrists prescribed more SGAPs and hospital‐based practitioners prescribed both generations equally, and these patterns changed across age ranges: For the elderly, GPs are the more frequent prescribers. SGAP/FGAP ratio is different by diagnostic categories. In France, FGAPs are largely prescribed by GPs mainly for the elderly, but young and adult patients are concerned as well. Inappropriate antipsychotic consumption through off‐label use, which adds to the co‐prescription, especially in vulnerable population groups, mainly concerns FGAP prescriptions by GPs who do not have psychiatric training and limited contact with psychiatrists. Attention should then be brought to the regulatory advisory agencies in order to better inform and train the prescribers

Spirometry practice by French general practitioners between 2010 and 2018 in adults aged 40 to 75 years

Abstract In France, most spirometries are performed by pneumologists. Spirometry is difficult to access due to the distance to medical office and long delays for appointments. This lack of accessibility contributes to the underdiagnosis of chronic obstructive pulmonary disease (COPD) among patients aged between 40 and 75 years. In recent years, general practitioners (GPs) have been performing spirometry in private practice. However, the extent of this practice is unknown. A French retrospective, repetitive transversal study analysed data from the “Système National des Données de Santé” (SNDS) database. The targeted population was GPs in primary care that performed spirometries between 2010 and 2018, in patients aged between 40 and 75 years. Between 2010 and 2018, 302,674 (7.2%) spirometries were performed in France by GPs in private practices, in patients 40 to 75 years old. 5.4% by “expert GPs” (>60 spirometries/year) and 1.8% by “non-expert GPs”. In “non-expert GPs” (2.8% of French GPs in 2018), the annual number of spirometries increased by 701 each year (p < 2.104), the annual number of GPs performing spirometries increased by 114 each year (p < 2.10−5). Overall, 24.9% of the spirometries performed by GPs were referrals from other GPs. The number of spirometries performed by GPs and the number of GPs performing spirometries has gradually increased over time. However, this increase is inadequate considering the need to early detect and follow up respiratory disorders

Association of psychiatric history with delay in the isotretinoin introduction among patients with severe acne. A French population-cohort study

International audienceNo abstract availabl

Descriptive study of colchicine prescriptions associated with a drug contraindication in patients living in Brittany based on health insurance data

International audienc

Analyse en vie réelle des séquences de traitement de patients initiant de l&amp;#039;abiratérone et de l&amp;#039;enzalutamide pour un cancer de prostate résistant à la castration métastatique

National audienceNous présentons ici les résultats ancillaires d&#039;une étude de cohorte française (SPEAR) incluant des patients initiant un traitement par abiratérone (ABI) et enzalutamide (ENZ) dans le cadre d&#039;un cancer prostate résistant à la castration métastatique (CRPCm) chimio-naïf, comparant survie globale ces traitements. L&#039;objectif est décrire séquences thérapeutiques durant deux ans qui ont suivi l&#039;initiation d&#039;ABI d&#039;ENZ. Le Système national données santé (SNDS) a été utilisé pour inclure SPEAR entre 2014 2018 présenter nombre lignes reçus patients. Via une analyse descriptive (« optimal matching ») utilisant différents états pris patient mensuellement depuis d&#039;ABI/ENZ (traité ABI/ENZ, chimio, décès...), clusters ayant plus grande ressemblance constitués sur période 0-12 mois puis 13-24 mois. L’âge, score Charlson durée d&#039;ADT fournis chaque cluster première année suivi. La incluait 10 308 dont 64 % 35 initié ABI ENZ, respectivement. Globalement, 52 n&#039;ont reçu qu&#039;une ligne traitement. Parmi mois, quel que soit initié, principaux concernaient poursuivant ABI/ENZ (54-65 respectivement) ceux interrompant leur mais restant en vie (14,5 groupes). sous-groupe avec ADT&lt;2 avant étaient fréquemment observés certains (clusters décès relai vers docétaxel) suggérant évolutif. Un ≥2 concernait 90 Nos suggèrent présentation similaire initiateurs Une meilleure connaissance l&#039;utilisation traitements CPRCm, réelle, permettra d&#039;améliorer utilisation stades précoces maladie, ce désormais recommandé. Cance

CO4.2 - Cost-effectiveness of an adaptive radiotherapy strategy to decrease xerostomia in locally advanced oropharynx carcinoma: An economic evaluation alongside the ARTIX Randomized Clinical Trial matched to the French National Health Insurance Database

International audienc

Major bleeding risk associated with oral anticoagulant in real clinical practice a multicenter population-based prospective cohort study over a period of 3 years

International audienc